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Abstract
Synaptic dysfunction plays a central role in Alzheimer’s disease (AD), since it drives the cognitive decline. An association
between a polymorphism of the adenosine A2A receptor (A2AR) encoding gene—ADORA2A, and hippocampal volume in
AD patients was recently described. In this study, we explore the synaptic function of A2AR in age-related conditions. We
report, for the first time, a significant overexpression of A2AR in hippocampal neurons of aged humans, which is aggravated
in AD patients. A similar profile of A2AR overexpression in rats was sufficient to drive age-like memory impairments in
young animals and to uncover a hippocampal LTD-to-LTP shift. This was accompanied by increased NMDA receptor
gating, dependent on mGluR5 and linked to enhanced Ca2+ influx. We confirmed the same plasticity shift in memory-
impaired aged rats and APP/PS1 mice modeling AD, which was rescued upon A2AR blockade. This A2AR/mGluR5/
NMDAR interaction might prove a suitable alternative for regulating aberrant mGluR5/NMDAR signaling in AD without
disrupting their constitutive activity.
Introduction
Synaptic dysfunction plays a central role in Alzheimer’s
disease (AD), since it drives the cognitive decline [1]. In
age-related neurodegeneration, cognitive decline has a
stronger correlation to early synapse loss than neuronal loss
in patients [2]. Despite the many clinical trials conducted to
identify drug targets that could reduce protein toxicity in
AD, such targets and such strategies proven unsuccessful.
Therefore, efforts focused on identifying the early
mechanisms of disease pathogenesis, driven or exacerbated
by the aging process, may prove more relevant to slow the
progression rather than the current disease-based models.
The array of synaptic proteins is complex and the
mechanisms underlying excitatory synaptic transmission are
finely tuned by synaptic activity. The activation of N-
methyl-D-aspartate (NMDA) receptors plays a pivotal role,
because it can induce either long-term potentiation (LTP) or
long-term depression (LTD), depending on the extent of the
resultant intracellular [Ca2+] rise in the dendritic spines and
the downstream activation of specific intracellular cascades
[3]. Indeed, the Aβ-triggered synaptic failure involves the
removal of AMPA receptors from the synaptic membrane
and the degradation of PSD95 protein at glutamatergic
synapses [4, 5]. In addition to NMDA receptors and AMPA
receptors, an involvement of the metabotropic glutamate
receptors (mGlu receptors) in Aβ mediated synaptic dys-
function has been suggested [6]. Shankar and colleagues [6]
demonstrated that different sources of Aβ (synthetic,
extracted from human brain or from cells) can facilitate
mGlu receptor-mediated LTD and can inhibit LTP leading
to a reduced dendritic spine density.
The role of LTP has been extensively studied in learning
and memory [7–9]. However, much less is known about
LTD and memory, either in physiological or pathological
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conditions. LTD is defined as a long-lasting weakening of a
synapse in response to a repeated low-frequency stimulation
[10, 11], being required for consolidation of hippocampal-
dependent spatial memory [12]. The trigger for inducing
activity-dependent LTD is predominantly an increase in
postsynaptic calcium (Ca2+). Since postsynaptic rises in
Ca2+ are implicated in the induction of both LTP and LTD
[13], it is widely accepted that larger rises in intracellular
Ca2+ result in LTP induction, while more modest increases
lead to LTD induction [14]. Some authors report increased
susceptibility to LTD during aging [15], whereas others fail
to observe alterations in LTD magnitude in aged animals
[16]. These discrepancies can be explained by differences in
animal strain, stimulation pattern or Ca2+/Mg2+ ratio.
Accordingly, age-related differences in LTD induction
could be rescued by manipulating the extracellular
Ca2+/Mg2+ ratio, consistent with the idea that changes in
Ca2+ regulation with advanced age may trigger increased
susceptibility to LTD [15, 17, 18]. However, the mechan-
isms leading to calcium alterations in LTD during normal
aging and age-related diseases remain mostly unexplored.
Recently, an association between a polymorphism of the
adenosine A2A receptor (A2AR) encoding gene—
ADORA2A, with hippocampal volume (synaptic loss) in
mild cognitive impairment and AD was reported [19]. This
polymorphism occurs in a non-coding region, upstream to
the coding sequence and it was just suggested, but not
studied, that it could imply alterations in A2AR expression.
There is compelling evidence from animal models of a
cortical and hippocampal upsurge of A2AR in glutamatergic
synapses upon aging and AD [20–26]. Such A2AR over-
activation induces glutamate release via PKA/cAMP/CREB
signaling [23, 25, 27, 28], calcium influx [29] and leads to
hippocampus-dependent cognitive deficits [30, 31]. Con-
versely, the blockade of A2AR, with either caffeine or more
selective antagonists (SCH 58261, KW6002, or MSX-3),
prevents hippocampus-dependent memory deficits and LTP
impairments in aged animals [32, 33] and in several AD
models [34–37]. Furthermore, knocking-out A2AR can rescue
stress and AD-related synaptic dysfunction [38, 39].
Accordingly, in humans, several epidemiological studies have
shown that regular caffeine consumption attenuates memory
disruption during aging and decreases the risk of developing
memory impairments in AD patients [34, 40–43]. Altogether,
these data suggest that A2AR might be a good candidate as
trigger to synaptic dysfunction in aging and AD.
We now explored the role of A2AR in hippocampal function
in age-related conditions. We showed a significant upsurge of
A2AR in hippocampal neurons of aged humans, a phenotype
aggravated in AD patients. Increased expression of A2AR driven
by the CaMKII promoter selectively in rat forebrain neurons
was sufficient to mimic aging-like memory impairments and to
uncover an LTD-to-LTP shift in the hippocampus. This shift
was due to an increased NMDA receptor gating and associated
to increased Ca2+ influx. We identified the mGluR5-NMDAR
interplay as key player in the observed A2AR-induced synaptic
dysfunction. Importantly, the same LTD-to-LTP shift was
observed in memory-impaired aged rats and APP/PS1 mice
modeling AD, a phenotype rescued upon A2AR blockade.
We not only prove that A2AR overexpression in young
animals is sufficient to drive age-like synaptic impairments,
but also explored this newly found interaction as a suitable
alternative for regulating aberrant mGluR5/NMDA signal-
ing without disrupting their constitutive activity. Due to the
aberrant A2AR signaling in pathological conditions
(reviewed in ref. [44]), their blockade is particularly rele-
vant for long-term therapies, since the alternative option of
targeting directly either mGluR5 or NMDAR interferes with
basal neuronal function and memory, as these proteins are
crucial components of the postsynaptic density.
Results
Increased levels of A2AR in human aged and
Alzheimer’s disease (AD) brain
There is a genetic association of the adenosine A2A receptor
encoding gene (ADORA2A) with hippocampal volume in
mild cognitive impairment and Alzheimer’s disease [19].
Plus, A2AR upregulation in cortex and hippocampus is
associated with memory dysfunction in different animal
models [45, 46]. We now probed this increase in human
brain of aged and AD subjects. A2AR expression was
measured in young (20–40 years old), aged (60–75 years
old) and AD (60–75 years old, Braak stages 5–6) forebrain.
There was a significant increase in A2AR protein levels in
the aged forebrain that was further enhanced in samples
from AD patients (Fig. 1a, b). The messenger RNA
(mRNA) quantification by quantitative PCR (qPCR) indi-
cates a 4.9 ± 0.3 (n= 3) fold increase in A2AR transcripts in
AD samples compared to aged samples (Fig. 1c). To assess
the cellular origin of this A2AR upregulation, we performed
a histological analysis of the hippocampi from AD patients
and age-matched controls. We detected a DAB-specific
staining for A2AR in aging and AD sections (Fig. 1d, e),
absent in the negative control (Supplementary Fig. 1a). In
both conditions, we observed a neuron-specific A2AR
positive staining (brown arrows; characterized by a large
hypochromatic nucleus with nucleolar inclusions). We did
not detect any significant A2AR signal in astrocytes (black
arrows; nuclei typically have pale, finely granular chromatin
patterns and relatively small or indistinct nucleoli), oligo-
dendrocytes (blue arrows; small, round, relatively dark
nuclei) or microglia (green arrows; rod-shaped and often
irregularly contoured nuclei) [47] (Fig. 1d).
M. Temido-Ferreira et al.
Physiopathological levels of A2AR in neurons impair
hippocampus-dependent spatial memory
Given that A2AR upregulation is associated with decreased
cognitive performance characteristic of aging and AD, we
studied a rat transgenic model with physiopathological
levels of A2AR expression to address the underlying
mechanism. These transgenic rats selectively overexpress
the human A2AR in neurons under the control of the
CaMKIIα promoter [Tg(CaMKII-hA2AR); Fig. 1f], mainly
in the cortex and hippocampus, in an aging-like pattern of
expression [23, 30]. The hippocampus displays a significant
overexpression of A2AR, particularly the DG and CA1, as
reported by the in situ A2AR mRNA human probe (Fig. 1f)
and immunostaining (Fig. 1g) and negligible expression in
other brain areas (see also [30]). Importantly, at
12–16 weeks of age, Tg(CaMKII-hA2AR) animals present a
5–8-fold increase of hippocampal A2AR immunoreactivity
[30], which is of the same magnitude as the increase found
in our human aged and AD samples (Fig. 1b), and
equivalent to that of aged rats [22]. To further evaluate the
profile of A2AR expression, co-staining for A2AR, GFAP,
and MAP2 was performed in hippocampal slices, confirm-
ing the upsurge in the neuropil and discarding the possibi-
lity of astrocytic A2AR expression in this model (Fig. 1g).
Biochemical fractionation of hippocampal tissue revealed a
clear enrichment of A2AR in the SNAP25 positive fraction,
in contrast to the low levels in the PSD95-enriched fraction,
favoring a mainly presynaptic localization (Fig. 1h), as
occurs for native A2AR in the rodent hippocampus [21, 48].
This was further confirmed by immunohistochemical ana-
lysis of the CA1 area of the hippocampus, in which the
A2AR signal overlaps with that of SNAP25, and not with
PSD95 signal (Supplementary Figs. 1b, c and 2a). This is
not due to lack of resolution since our system was able to
resolve a control section labeled for both a pre- and a
postsynaptic protein (Supplementary Fig. 2b).
Accordingly, immunoelectron micrographs of the CA1
area of Tg(CaMKII-hA2AR) reveal a preferential pre-
synaptic localization of A2AR (Fig. 1i). We then evaluated
hippocampus-dependent spatial memory using the Morris
water maze (MWM) test. Transgenic animals displayed a
decrease in acquisition (Fig. 2a) and a lack of preference for
the target quadrant during the probe test (Fig. 2b). We did
not find differences in swimming speed between groups
(Fig. 2c).
Increased levels of A2AR enhance glutamate release
probability
To further dissect the mechanism by which A2AR impair
memory performance, whole-cell patch-clamp recordings
were performed. We first measured the intrinsic excitability
of CA1 neurons from Tg(CaMKII-hA2AR) and WT rats. No
changes were observed in passive properties (resting
membrane potential or membrane resistance), nor in single
spike analysis of the studied populations of neurons
(Supplementary Fig. 3a, b). Moreover, neurons from WT
and Tg(CaMKII-hA2AR) animals exhibited similar behavior
when submitted to steps of current injection (Supplementary
Fig. 3c–h). Thus, A2AR overexpression does not impact on
the studied passive or intrinsic excitability properties of
CA1 neurons. We then performed afferent-evoked EPSCs
from CA1 pyramidal neurons (Vh=−70 mV), in the pre-
sence of GABAA receptor antagonist picrotoxin (50 µM).
A2AR blockade significantly inhibited excitatory post-
synaptic currents (EPSCs), an effect that was not observed
in WT animals (Fig. 2d, e). Thus, there is a gain of
function of A2AR upon their overexpression, whereby
A2AR tonically control basal synaptic transmission in Tg
(CaMKII-hA2AR) animals, which does not occur in WT
animals.
To test if tonic A2AR modulation of neuronal function
occurs at a presynaptic level, we evaluated the glutamate
release probability. A facilitation of the paired-pulse ratio
(PPR) was observed in neurons from WT animals at all
inter-stimulation intervals, more evident for the shorter
intervals (Supplementary Fig. 3i). The magnitude of facil-
itation was reduced in Tg(CaMKII-hA2AR) rats when
compared to WT neurons (Supplementary Fig. 3i), albeit
maintaining the same facilitatory profile. These data suggest
that neuronal A2AR overexpression increases glutamate
release probability [49, 50]. These PPR alterations in Tg
(CaMKII-hA2AR) rats were completely rescued by the
A2AR selective antagonist, SCH 58261 (Supplementary
Fig. 3i). As expected, A2AR blockade does not alter PPR
values in WT animals (Supplementary Fig. 3i).
A2AR increase NMDAR-mediated currents in CA1
pyramidal neurons
A2AR were proposed to mainly modulate NMDA receptors
(NMDAR) [51–53], which are minor contributors to exci-
tatory synaptic transmission under basal conditions in the
hippocampus [54]. We tested possible alterations of the
AMPA and NMDA receptor contribution, by quantifying
the AMPA/NMDA receptor ratio. The AMPA/NMDA
receptor ratio was decreased in Tg(CaMKII-hA2AR) vs. WT
animals (Fig. 2f). To assess if this could be attributed to
changes in the gating properties of the receptors, we per-
formed current–voltage (I–V) relationships in pharmacolo-
gically isolated AMPAR and NMDAR responses. While the
I–V relationships of the NMDAR were significantly
increased in neurons from Tg(CaMKII-hA2AR) animals
(Fig. 2g), the AMPAR voltage-dependency was unaltered in
Tg(CaMKII-hA2AR) neurons (Supplementary Fig. 3j).
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Moreover, we calculated the ratio between NMDAR current
recorded at+ 40 mV and at −60 mV, and observed it was
significantly increased in Tg(CaMKII-hA2AR) neurons
(Fig. 2h).
In the hippocampus, NMDARs are heteromeric assem-
blies mainly composed of a constitutive GluN1 subunit and
GluN2A or GluN2B subunits [55]. The deactivation time
course of GluN1/GluN2B heteromers is higher than the one
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observed for GluN1/GluN2A heteromers [56]. To test if
NMDAR overactivation was due to alterations in NMDAR
subunit composition, we analyzed the deactivation kinetics
of pharmacologically isolated NMDAR EPSCs. Time con-
stants for fast, slow and weighted components (τfast, τslow,
and τweighted) were obtained by fitting the pharmacologically
isolated NMDAR EPSCs (Vh=+ 40 mV) to a double
exponential function (Levenberg-Marquandt method). No
differences were found between groups for all parameters
evaluated (Fig. 2i), suggesting that the enhancement of
NMDAR conductance observed in Tg(CaMKII-hA2AR)
neurons is not related to alterations in NMDAR subunit
composition.
Physiopathological levels of A2AR lead to a NMDAR-
mediated LTD-to-LTP shift
In view of the key role of NMDAR in the control of
synaptic plasticity we next focused on the impact of A2AR
overexpression on long-term depression (LTD) in the CA1
area of the dorsal hippocampus. LTD is altered in associa-
tion with memory deficits in aging [57] and animal models
of stress [58] or AD [59]. In the hippocampus, LTD can be
experimentally induced using several different protocols,
including both electrical and pharmacological stimulation
[60]. For our purpose, we selected a low-frequency stimu-
lation (LFS) protocol particularly efficient in inducing
robust LTDs in adult animals—three trains of 1200 pulses,
2 Hz, 10-min interval [39, 61].
We observed a significant alteration of the pattern of
induction of LTD: whereas this protocol triggered a typical
LTD in WT animals, it generated instead a significant LTP
in Tg(CaMKII-hA2AR) animals (Fig. 3a).
The pattern of activation of NMDAR controls the entry
of calcium into the postsynaptic compartment, determining
the output of plasticity [14, 62]. The robust recruitment of
NMDAR causes a large calcium influx driving LTP,
whereas the engagement of a lower number of NMDAR
causes a more discrete calcium influx culminating in LTD
[14, 62]. To confirm a greater NMDAR role in this LTD-to-
LTP shift in Tg(CaMKII-hA2AR) animals, we induced LTD
and titrated the recruitment of NMDAR using increasing
concentrations of the NMDAR antagonist, AP5 (Fig. 3b, c).
With a low concentration of AP5 (15 µM), the LTP
observed in Tg(CaMKII-hA2AR) animals was abolished.
Further increase of the AP5 concentration to 50 µM con-
verted the LTP into LTD, fully rescuing the abnormal
plasticity profile in Tg(CaMKII-hA2AR) to a WT-like phe-
notype. Further increase of AP5 concentration to a supra-
maximal value of 100 µM abolished LTD, confirming that
LTD in Tg(CaMKII-hA2AR) animals is still strictly
NMDAR-dependent (Fig. 3c). In WT animals, LTD mag-
nitude did not change with 15 µM of AP5 (Fig. 3c), but
when NMDAR were blocked with AP5 at 50 µM, no LTD
was elicited, as expected (Fig. 3c). Consistent with an
aberrant NMDAR contribution to basal transmission in Tg
(CaMKII-hA2AR) animals, we observed a decrease in
fEPSPs slope with AP5 (50 µM) in Tg(CaMKII-hA2AR)
animals, but not in WT animals (Fig. 3d). Acute blockade of
A2AR directly on slices rescued the LTD shift observed in
Fig. 1 Increased levels of A2AR in human aged and Alzheimer’s dis-
ease (AD) brain. a Representative image of the western blot for A2AR
in human prefrontal cortex and the internal control Pan-cadherin.
b A2AR immunoreactivity in young, aged, and AD human cortex
(*p < 0.05, ***p < 0.001 comparing to young subjects, #p < 0.05
comparing to aged subjects, one-way ANOVA followed by a Tukey’s
multiple comparisons post hoc test) (n= 3, 2, and 3, respectively).
c Increase in A2AR mRNA in AD human brain when compared with
age-matched control subjects (###p < 0.001 comparing to healthy age-
matched subjects, unpaired t-test) (n= 3). d In human AD and age-
matched control hippocampal sections, positive staining for A2AR is
present (scale bar: 200 µm). Within hippocampus, A2AR upsurge is
neuronal specific, since positive labeling is observed in neurons
(brown arrows; cells with large hypochromatic nucleus with nucleolar
inclusions), while in astrocytes (black arrows; astrocytic nuclei typi-
cally have pale, finely granular chromatin patterns and relatively small
or indistinct nucleoli), oligodendrocytes (blue arrows; characterized by
small, round, relatively dark nuclei) and microglia (green arrows; cells
with rod-shaped and often irregularly contoured nuclei) A2AR is not
detected (scale bar: 100 µm). e DAB immunostaining quantification in
negative control, aged, and AD samples (*p < 0.05, ***p < 0.001
comparing to negative control, #p < 0.05 comparing to aged, one-way
ANOVA followed by a Bonferroni’s multiple comparisons post hoc
test) (n= 4, 4, and 3, respectively). f Construct used to generate Tg
(CaMKII-hA2AR) rats; Tg(CaMKII-hA2AR) animals present an over-
expression of total A2AR in the hippocampus evaluated by in situ
hybridization (both with the hA2AR probe and through cross-
hybridization of the rat A2AR probe to the human A2AR mRNA).
g Compositional images of fluorescence immunohistochemistry of
hippocampus of WT and Tg(CaMKII-hA2AR) animals (scale bar:
1000 μm). Nuclei are labeled in blue (with Hoechst) and A2AR in red.
A2AR staining is present in hippocampal areas of Tg(CaMKII-hA2AR)
animals but not in WT littermates. Within the hippocampus, positive
labeling can be observed in CA3 axonal projections and strong
staining is also observed in the neuropil of DG and CA1 areas. On the
top, z-stack maximum intensity projection images taken at 100 ×
magnification in CA1 area of hippocampus are presented (scale bar:
15 μm). MAP2 positive cells are identified by green fluorescence.
A2AR staining can be observed in the neuropil of CA1 area in Tg
(CaMKII-hA2AR) hippocampal slices. At the middle and bottom
panels, a z-stack maximum intensity projection image taken at 100 ×
magnification in CA1 area of hippocampus is presented (scale bar:
15 μm). GFAP positive cells are identified by green fluorescence. No
co-localization is found between A2AR and GFAP staining. h Immu-
noblotting analysis after subcellular fractionation of hippocampal tis-
sue from WT and Tg(CaMKII-hA2AR) animals. i Electron
micrographs of the area where the recordings were conducted in the
hippocampus of Tg(CaMKII-hA2AR) animals showing immunogold
particles for A2AR in the presynaptic neuron. On top, intracellular
distribution of nanoparticles reveal a preferential presynaptic locali-
zation of A2AR. On the right, duplicates of the images with the iden-
tification of the subcellular structures. Pre presynaptic neuron, Post
postsynaptic neuron, Mit mitochondria, SynV synaptic vesicle.
Uncropped gels and blots with molecular weight standards are pro-
vided in Supplementary Fig. 6. All values are mean ± SEM
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Fig. 2 Physiopathological levels of A2AR in neurons impair
hippocampus-dependent spatial memory and increase NMDAR currents
in CA1 pyramidal neurons. a, b Hippocampal-dependent memory per-
formance was assessed by the MWM test, in which acquisition (a) (*p <
0.05, two-way ANOVA) (n= 6 and 8, respectively) and retention
(b) (***p < 0.001, one-way ANOVA followed by a Bonferroni’s mul-
tiple comparisons post hoc test within groups) (n= 6 and 8, respectively)
were evaluated. c No changes in swimming speed during probe test
between WT and Tg(CaMKII-hA2AR) animals (n= 6 and 8, respec-
tively). d Top left, schematic representation of the simplified circuitry of
the hippocampus. A stimulation electrode was placed in the Schaffer
collaterals and the recording electrode patching a pyramidal cell of the
CA1 area. Top right, pyramidal area of the CA1 with a recording elec-
trode patching one cell. Graph: Averaged time course of excitatory
postsynaptic currents after perfusion with SCH 58261 (50 nM) for 30
min, in neurons from WT and Tg(CaMKII-hA2AR) animals (**p < 0.01,
unpaired t-test) (n= 4). Black traces represent baseline, while gray traces
correspond to the EPSCs 20–30min after SCH 58261 perfusion.
e Averaged EPSCs (change in EPSCs from the last 10min of
SCH 58261 application) from acute SCH 58261 perfusion experiments.
(**p < 0.01, unpaired t-test) (n= 4). f AMPAR/NMDAR ratio in neu-
rons from WT and Tg(CaMKII-hA2AR) animals (*p < 0.05, unpaired t-
test) (n= 16 and 20, respectively); representative traces of EPSCs
recorded at −70mV and+ 40mV, arrows indicate the amplitudes
considered to calculate AMPAR/NMDAR ratio. g Plots of normalized
EPSCNMDA current–voltage relationships recorded in the presence of
DNQX (100 µM) from WT and Tg(CaMKII-hA2AR) neurons (*p < 0.05,
two-way ANOVA) (n= 14 and 7, respectively); representative traces
of NMDAR EPSCs recorded at −70mV and + 40mV. h NMDAR
EPSC+40mV/EPSC-60mV ratio from WT and Tg(CaMKII-hA2AR) neurons
(**p < 0.01, unpaired t-test) (n= 14 and 7, respectively). i Average time
constants for fast and slow components (τfast and τslow) of NMDAR
EPSC recorded in neurons from WT and Tg(CaMKII-hA2AR) animals
(n= 14 and 7, respectively). All values are mean ± SEM
M. Temido-Ferreira et al.
Tg(CaMKII-hA2AR) animals. In fact, LFS stimulation of Tg
(CaMKII-hA2AR) slices with either SCH 58261 (50 nM) or
the non-selective adenosine antagonist, caffeine (30 µM)
triggered an LTD similar to that found in WT animals
(Fig. 3e–g). As expected, in WT animals, this A2AR
blockade did not change LTD magnitude (Fig. 3g).
Accordingly, SCH 58261, 50 nM, significantly decreased
basal field excitatory post-synaptic potentials (fEPSPs) in
Tg(CaMKII-hA2AR) animals, while no effect was observed
in WT (Supplementary Fig. 3k), confirming that the effects
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seen in Tg(CaMKII-hA2AR) animals are indeed due to
A2AR overactivation.
Group I metabotropic glutamate receptors, namely
mGluR5, are postsynaptic and tightly coupled to NMDA
receptors [51, 63, 64], conferring them the ability to
exacerbate NMDAR-mediated toxicity. Upon activation by
glutamate release, preferentially upon strong synaptic acti-
vation, they increase NMDAR-mediated Ca2+ currents [65].
When we blocked mGluR5 with MPEP, 5 µM, the LTD-to-
LTP shift observed in Tg(CaMKII-hA2AR) animals was
prevented (Fig. 3h). Consistent with their activation
upstream of NMDAR, the aberrant NMDAR component in
Tg(CaMKII-hA2AR) disappeared upon mGluR5 blockade
(Fig. 3d), disclosing mGluR5 as a player in the observed
A2AR-induced synaptic dysfunction. MPEP does not change
AP5-induced basal transmission or LTD magnitude in WT
animals (Supplementary Fig. 3l, m).
To further study the alterations in the threshold for LTD
in Tg(CaMKII-hA2AR) animals, we elicited LTD using
decreasing frequencies of stimulation maintaining the total
number of pulses of one train (1200): 2, 1, and 0.5 Hz. In
contrast to what we observed for 3 × trains of 1200 pulses
(2 Hz), a lower 0.5 Hz frequency was more effective in
inducing LTD in Tg(CaMKII-hA2AR) than in WT animals
(Fig. 3i and Supplementary Fig. 4a). Furthermore, fre-
quencies of 1 and 2 Hz failed to elicit LTD in both WT and
Tg(CaMKII-hA2AR) (Supplementary Fig. 4b, c). More
importantly, the magnitude of LTD in Tg(CaMKII-hA2AR)
animals correlated significantly with the frequency of sti-
mulation (Fig. 3i), consistent with a shift to the left in the
LTD threshold.
Blockade of A2AR activation in vivo rescues the LTD-
to-LTP shift in Tg(CaMKII-hA2AR) animals
To establish that A2AR overactivation is indeed the trigger
for the aberrant NMDAR recruitment, we treated Tg
(CaMKII-hA2AR) animals with the A2AR selective antago-
nist KW6002 (5 mg/kg/day), in the drinking water for
4 weeks. In Tg(CaMKII-hA2AR)-treated animals, LFS
induced an LTD comparable to WT animals, rescuing the
LTD-to-LTP shift (Fig. 3j, k). Furthermore, the KW6002
treatment normalized NMDAR overactivation, as confirmed
Fig. 3 Physiopathological levels of A2AR lead to a NMDAR-mediated
LTD-to-LTP shift. a Top, schematic representation of the simplified
circuitry of the hippocampus. A stimulation electrode was placed in
the Schaffer collaterals and the recording electrode in the pyramidal
layer of the CA1 area. Graph: Changes in fEPSP slope induced by LFS
stimulation (three trains of 1200 pulses, 2 Hz) recorded from WT and
Tg(CaMKII-hA2AR) hippocampal slices (**p < 0.01, unpaired t-test)
(n= 6 and 7, respectively); representative traces of fEPSPs before
(black) and 50–60 min after (gray, red) LTD induction in WT and Tg
(CaMKII-hA2AR) animals. b Changes in fEPSP slope induced by LFS
stimulation (three trains of 1200 pulses, 2 Hz) recorded from WT and
Tg(CaMKII-hA2AR) hippocampal slices after partial and complete
NMDAR blockade with AP5 (15 and 50 µM, respectively) (****p <
0.0001 comparing to Tg(CaMKII-hA2AR), two-way ANOVA fol-
lowed by Bonferroni’s multiple comparisons post hoc test) (n= 4 and
3, respectively); representative traces of fEPSPs before (black) and
50–60 min after (gray, red, blue) LTD induction in WT, Tg(CaMKII-
hA2AR) and Tg(CaMKII-hA2AR) animals with NMDAR complete
blockade. c Effect of increasing AP5 concentrations (0–100 µM) on
synaptic strength after low-frequency stimulation (changes after 50-60
min) in WT and Tg(CaMKII-hA2AR) animals (*p < 0.05, ***p <
0.001, two-way ANOVA followed by Bonferroni’s multiple compar-
isons post hoc test) (WT: n= 6, 4, and 4, respectively; Tg(CaMKII-
hA2AR): n= 7, 4, 3, and 3, respectively). d mGluR5 blockade rescues
the effect of AP5 on basal transmission in Tg(CaMKII-hA2AR) ani-
mals (*p < 0.05 comparing to WT, one-way ANOVA followed by
Bonferroni’s multiple comparisons post hoc test) (n= 3). e Changes in
fEPSP slope induced by LFS stimulation recorded from WT, Tg
(CaMKII-hA2AR) and Tg(CaMKII-hA2AR) hippocampal slices per-
fused with SCH 58261 (50 nM) (*p < 0.05 comparing to Tg(CaMKII-
hA2AR), two-way ANOVA followed by Bonferroni’s multiple com-
parisons post hoc test) (n= 6, 7, and 3, respectively); representative
traces of fEPSPs before (black) and 50–60 min after (gray, red, dark
red) LTD induction in WT, Tg(CaMKII-hA2AR) and Tg(CaMKII-
hA2AR) animals with SCH 58261. f Changes in fEPSP slope induced
by LFS stimulation recorded from WT, Tg(CaMKII-hA2AR) and Tg
(CaMKII-hA2AR) hippocampal slices perfused with caffeine (30 µM)
(**p < 0.01 comparing to Tg(CaMKII-hA2AR), two-way ANOVA
followed by Bonferroni’s multiple comparisons post hoc test) (n= 6,
7, and 4, respectively); representative traces of fEPSPs before (black)
and 50–60 min after (gray, red, dark red) LTD induction in WT, Tg
(CaMKII-hA2AR) and Tg(CaMKII-hA2AR) animals with caffeine.
g Changes in fEPSP slope induced by LFS stimulation recorded from
WT and Tg(CaMKII-hA2AR) perfused with SCH 58261 (50Mn) or
caffeine (30 µM) (**p < 0.01 comparing to WT, #p < 0.05, ##p < 0.01
comparing to Tg(CaMKII-hA2AR), two-way ANOVA followed by
Bonferroni’s multiple comparisons post hoc test) (WT: n= 5).
h Changes in fEPSP slope induced by LFS stimulation recorded from
WT, Tg(CaMKII-hA2AR) and Tg(CaMKII-hA2AR) hippocampal slices
perfused with mGluR5 antagonist MPEP (5 µM) (**p < 0.01 com-
paring to Tg(CaMKII-hA2AR), two-way ANOVA followed by Bon-
ferroni’s multiple comparisons post hoc test) (n= 6, 7, and 4,
respectively). i Changes in fEPSP slope induced by increasing fre-
quencies of LFS stimulation in WT and Tg(CaMKII-hA2AR) animals
(*p < 0.05, ***p < 0.001, two-way ANOVA followed by Bonferroni’s
multiple comparisons post hoc test) (WT: n= 4, 3, 3, and 6, respec-
tively; Tg(CaMKII-hA2AR): 4, 4, 4, and 7, respectively). j Changes in
fEPSP slope induced by LFS stimulation (three trains of 1200 pulses,
2 Hz) in WT and Tg(CaMKII-hA2AR) animals non-treated (CTR) and
treated with KW6002 (**p < 0.01 comparing to Tg(CaMKII-hA2AR,
two-way ANOVA followed by Bonferroni’s multiple comparisons
post hoc test) (n= 6). AP5, 50 µM, abolished LTD in Tg(CaMKII-
hA2AR) animals treated with KW6002 (n= 4); representative traces of
fEPSPs before (black) and 50–60 min after (red, blue) LTD induction
in Tg(CaMKII-hA2AR) chronically treated with KW6002 in the
absence and presence of AP5. k Changes in fEPSP slope induced by
LFS stimulation recorded from WT and Tg(CaMKII-hA2AR) animals
non-treated (CTR) and treated with KW6002, in the presence and
absence of AP5 (50 µM). (**p < 0.01 comparing to WT, #p < 0.05
comparing to Tg(CaMKII-hA2AR), two-way ANOVA followed by
Bonferroni’s multiple comparisons post hoc test) (WT: n= 6, 4, and 3,
respectively; Tg(CaMKII-hA2AR): n= 7, 5, and 4, respectively).
l Chronic KW6002 treatment reverts the effect of AP5 on basal
transmission in Tg(CaMKII-hA2AR) animals (*p < 0.05 comparing to
WT, one-way ANOVA followed by Bonferroni’s multiple compar-
isons post hoc test) (n= 3). All values are mean ± SEM
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by the reinstatement of AP5 ability to fully block LTD in Tg
(CaMKII-hA2AR) (Fig. 3j, k). The treatment with KW6002
did not change LTD magnitude in WT animals (Fig. 3k),
nor A2AR mRNA relative expression in both WT and Tg
(CaMKII-hA2AR) (Supplementary Fig. 4d). The increased
NMDAR contribution to basal transmission observed in Tg
(CaMKII-hA2AR) animals disappeared upon chronic
KW6002 treatment (Fig. 3l).
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Increased levels of A2AR impair calcium homeostasis
To investigate whether A2AR-mediated NMDAR hyper-
activation disrupted Ca2+ signaling, we measured variations
in intracellular calcium concentrations ([Ca2+]i) in
primary neuronal cultures transfected with A2AR. For this,
we used a construct encoding a Venus-A2AR fusion protein.
We confirmed the co-localization of the Venus signal
with the immunostaining for A2AR (Fig. 4a). Changes in
[Ca2+]i were detected by Ca2+ imaging using Fura 2-
acetoxymethyl ester (Fura-2 AM) (Fig. 4b). Application
of the A2AR agonist CGS 21680, 30 nM, elevated intra-
cellular Ca2+ levels in Venus-A2AR transfected neurons,
whereas in non-transfected neurons lower changes in
fluorescence were detected (Fig. 4c, g and Supplementary
Video 1). This A2AR-evoked increase in [Ca
2+]i was pre-
vented by the NMDAR antagonist, AP5, 50 μM (Fig. 4d, h),
the A2AR antagonist, SCH 58261, 50 nM (Fig. 4e, i) or
mGluR5 antagonist MPEP, 5 μM (Fig. 4f, j). These results
show for the first time a crosstalk between A2AR and
NMDAR that impacts on Ca2+ influx in glutamatergic
neurons.
LTD-to-LTP shift in aged and APP/PS1 animals is
rescued by A2AR blockade
Aging and AD are associated with an upregulation of A2AR
in the hippocampus as we report here (Fig. 1) and others
have shown previously [20, 21, 23, 66]. We evaluated
putative LTD impairments in aged animals and in an APP/
PS1 mouse model of AD, both models displaying A2AR
increased levels (Supplementary Fig. 4e, f).
Aged animals displayed the same LTD-to-LTP shift to
that observed in our Tg(CaMKII-hA2AR) animals, while in
young animals a robust LTD was achieved (Fig. 5a, b). The
LTD-to-LTP shift was completely rescued with A2AR
blockade by SCH 58261 (Fig. 5a, b), whereas SCH 58261
did not alter LTD profile in young animals (Fig. 5b). Within
the aged group, we identified a subset of age-impaired
animals that performed worse than young rats in the Y-
maze test, revealing no preference for the novel arm
(Fig. 5c). Interestingly, these same animals seem to be
distinguished by an LTD-to-LTP shift, also observed in Tg
(CaMKII-hA2AR) (Fig. 5d). In contrast, age-unimpaired
animals performed within the range of young rats (Fig. 5c)
and could be distinguished their lack of response to LFS
(Fig. 5d). Consistent with the enhanced role of A2AR upon
aging [23, 25, 28], SCH 58261 decreased basal transmission
in hippocampal slices of aged animals, while no effect was
observed in young animals (Supplementary Fig. 4g). We
observed a tendency towards an increased effect of SCH
58261 in age-impaired subset (Supplementary Fig. 4h),
when compared with age-unimpaired animals, in spite of
the lower n. This larger tonic effect of adenosine suggests
an increased A2AR activation in age-impaired animals.
Importantly, we found that plasticity profile correlated sig-
nificantly with the behavioral memory index in aged rats
(Fig. 5e), whereby a higher LTD-to-LTP shift corresponded
to a worse Y-maze performance. Notably, a 3-week treat-
ment with the selective A2AR antagonist (KW6002; 5 mg/
Kg/day; oral) restored memory impairments, as observed by
the increased time spent in the novel arm (Fig. 5c). This
KW6002 treatment did not affect A2AR mRNA expression
in aged animals (Supplementary Fig. 4e), consistent to what
was observed for Tg(CAMKII-hA2AR) animals (Supple-
mentary Fig. 4d).
In 11–12 months old APP/PS1 mice, these animals dis-
play memory deficits [67] and LFS elicited LTP instead of
LTD (Fig. 5f, g), as seen in Tg(CaMKII-hA2AR) animals.
Importantly, acute blockade of A2AR with 100 nM SCH
58261, was able to revert the LTD-to-LTP shift back to the
LTD characteristic of WT mice (Fig. 5f, g).
Fig. 4 Increased levels of A2AR impair calcium homeostasis. a Control
immunocytochemistry analysis of neurons transfected with Venus-
A2AR construct confirmed co-expression of Venus and A2AR.
b Representative images of Ca2+ imaging. Bright regions indicate the
location of cytoplasm and organelles, where the concentration of Ca2+
is higher than in the dark regions indicating the extracellular medium,
where diffusion processes take place. The right image corresponds to
the ratio between the radiation emitted at 510 nm, when cells are
excited at 340 nm, over emission upon excitation at 380 nm (F340/
F380). c Time course of Ca2+-dependent fluorescence recorded and
averaged per minute from Fura-2 AM neurons transfected with Venus-
A2AR construct in response to CGS 21680, 30 nM, and ionomycin, 2
µM. Application of A2AR agonist CGS 21680, 30 nM, elevated
intracellular Ca2+ levels in Venus-A2AR transfected neurons, whereas
lower changes in fluorescence were detected in non-transfected neu-
rons (*p < 0.05, unpaired t-test). Time of application of drugs are
shown by arrows. (4–15 responsive cells per experimental condition
from three independent cultures). d Time course of Ca2+-dependent
fluorescence recorded and averaged from Fura-2 AM neurons trans-
fected with Venus-A2AR construct in response to AP5, 50 µM, CGS
21680, 30 nM, and ionomycin, 2 µM. The A2AR-evoked increase in
[Ca2+]i observed in c) was prevented by NMDAR antagonism (4–15
responsive cells per experimental condition from two independent
cultures). Time of application of drugs are shown by arrows. e Time
course of Ca2+-dependent fluorescence recorded and averaged from
Fura-2 AM neurons transfected with Venus-A2AR construct in
response to SCH 58261, 50 nM, CGS 21680, 30 nM, and ionomycin,
2 µM. The A2AR-evoked increase in [Ca
2+]i observed in c) was pre-
vented by A2AR antagonism (4–15 responsive cells per experimental
condition from two independent cultures). Time of application of
drugs are shown by arrows. f Time course of Ca2+-dependent fluor-
escence recorded and averaged from Fura-2 AM neurons transfected
with Venus-A2AR construct in response to MPEP, 5 µM, CGS 21680,
30 nM, and ionomycin, 2 µM. The A2AR-evoked increase in [Ca
2+]i
observed in c) was prevented by mGluR5 antagonism (4–15 respon-
sive cells per experimental condition from three independent cultures).
Time of application of drugs are shown by arrows. g, h, i, j Repre-
sentative images of the different conditions showed in (c, d, e), and
f, respectively. All values are mean ± SEM
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Discussion
We show that the A2AR upsurge, described in different
pathological situations in rodent models, such as hypoxia,
ischemia, stress, diabetes, and even upon aging [44], is also
characteristic of the human aged brain and is aggravated in
AD [68]. Moreover, we describe that an increase in neu-
ronal A2AR is sufficient to drive deficits in synaptic
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Fig. 5 LTD-to-LTP shift in aged and APP/PS1 animals is rescued by A2AR blockade. a, b Changes in fEPSP slope induced by LFS stimulation
recorded from young and aged animals upon acute A2AR blockade (SCH 58261, 50 nM) (*p < 0.05 comparing to young,
#p < 0.05 comparing to
aged, two-way ANOVA followed by Tukey’s multiple comparisons post hoc test) (Young: 3 and 4, respectively; Aged: 6 and 7, respectively);
representative traces of fEPSPs before (black) and 50–60 min after (gray, green, dark green) LTD induction in young, aged, and aged animais
treated with SCH 58261, respectively. c Spatial memory performance was assessed by the Y-Maze test. Aged animals displayed a loss of
preference for the novel arm (***p < 0.001, ****p < 0.0001, novel arm comparing to other arm, two-way ANOVA followed by Bonferroni’s
multiple comparisons post hoc test) (young: n= 10; aged: n= 15). The pool of aged rats included a substantial subset of rats that performed within
the range of young rats, labeled age-unimpaired rats (n= 6), while other clearly showed impairment, labeled age-impaired rats (n= 9), that is
rescued upon chronic KW6002 treatment (**p < 0.01, novel arm comparing to other arm, two-way ANOVA followed by Bonferroni’s multiple
comparisons post hoc test) (n= 4). d Age-impaired animals exhibited a LTD-to-LTP shift (*p < 0.05 comparing to WT, one-way ANOVA
followed by a Bonferroni’s multiple comparisons post hoc test) (n= 3). Age-unimpaired animals can be distinguished by their lack of response to
LFS (n= 3). e LTD magnitude observed in aged animals significantly correlates with Y-maze preference index (three replicates of n= 6 animals,
r2= 0.30, p < 0.05). f, g Changes in fEPSP slope induced by LFS stimulation recorded from WT, APP/PS1 mice, and APP/PS1 hippocampal slices
perfused with SCH 58261 (100 nM) (***p < 0.001 comparing to WT, ##p < 0.01 comparing to APP/PS1, one-way ANOVA followed by a
Bonferroni’s multiple comparisons post hoc test) (n= 4, 4, and 3, respectively); representative traces of fEPSPs before (black) and 50–60 min after
(gray, orange) LTD induction in WT, APP/PS1 and APP/PS1 SCH 58261 100 nM. All values are mean ± SEM
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plasticity, leading to an LTD-to-LTP shift and impairments
of hippocampal-dependent learning and memory. This is a
consequence of an A2AR-induced increase in postsynaptic
Ca2+ influx via NMDAR, which is dependent on mGluR5
activation (see Supplementary Fig. 5 for a summary). We
reveal that the same synaptic plasticity shift occurs in the
hippocampus of aged and APP/PS1 animals, which is res-
cued upon A2AR blockade.
The findings in human hippocampal samples confirm the
observations made in animal models, in which A2AR den-
sity is increased upon aging [20, 22–24, 69]. Accordingly,
in humans, several epidemiological studies have shown that
regular caffeine consumption attenuates memory disruption
during aging and decreases the risk of developing memory
impairments in AD patients [34, 40–43]. Furthermore, in
animal models of several other pathologies, there is a clear
correlation of hippocampal A2AR upregulation with cogni-
tive deficits, such as in acute or chronic stress [38, 45, 70],
Alzheimer’s [26], Parkinson’s [71], or Huntington’s dis-
eases [72, 73]. However, the exact mechanism by which
neuronal A2AR overactivation could trigger or increase the
susceptibility for memory dysfunction in these multiple
pathologies was not known.
A previous study using a model of A2AR overexpression
under the control of the neuron-specific enolase promoter
reported working memory deficits [74]. However, that study
could not distinguish A2AR-related embryonic effects from
those elicited by postnatal alterations. In contrast, our model
of overexpression, driven by a CaMKII promoter, allows a
progressive postnatal and forebrain-specific expression,
bypassing developmental effects and closer to an age-like
A2AR distribution. These animals exhibit depressive-like
behavior, hyperlocomotion, and altered exploratory beha-
vior, consistent with the depressive signs found in aging,
chronic stress, and AD [75]. Importantly, they do not pre-
sent changes in adenosine A1 receptor levels nor adenosine
levels in the hippocampus [30]. Furthermore, at 12 week-
old, the Tg(CaMKII-hA2AR) animals display a 5–8-fold
increase of A2AR immunoreactivity [30], which is in the
same magnitude of that found in our human aged and AD
samples, and equivalent to that of aged rats [20–22, 25].
Importantly, this A2AR overexpression occurs in the hip-
pocampus and cortex, recapitulating the pattern observed in
our aged and AD human samples and consistent with pre-
vious reports [68]. In the Tg(CaMKII-hA2AR) model there
is no evidence of A2AR overexpression in astrocytes,
strengthening the idea that the observed memory and
synaptic impairments are due to a neuronal-specific A2AR
overexpression. The fact that in aged and AD human
samples we observed a clear A2AR overexpression in neu-
rons further emphasizes neuronal A2AR as key mediators in
synaptic glutamatergic dysfunction observed in aging and
AD [76]. Aberrant astrocytic A2AR expression in late-stage
AD has been associated to cognitive decline, and indeed
astrocytic A2AR can lead to alterations of synaptic A2AR-
mediated functions [77]. However, neuronal contribution is
highlighted by recent evidence showing that stimulation of
neuronal opto-A2AR in the hippocampus induces changes in
synaptic plasticity and CREB activation [27]. Moreover,
silencing A2AR in neurons of the associative/commissural
pathway rescues the aberrant LTP in APP/PS1 mice in a
non-NMDAR-dependent mechanism [26, 27]. Our findings
demonstrate that neuronal A2A overactivation is sufficient to
induce synaptic dysfunction and cognitive impairments.
This suggests that synaptic dysfunction in aging and early
stages of AD may be driven predominantly by a neuronal
A2AR progressive dysfunction, whereas at later Braak stages
of AD, astrocytic A2AR and inflammation might become
more relevant [39, 76].
Both aging and AD comprehend functional and struc-
tural alterations in the hippocampus that drive cognitive
decline [1, 78]. Furthermore, they are also characterized by
an abnormal Ca2+ signaling. Several studies reported an
age-associated increase in basal [Ca2+]i levels [79, 80] and
action potential-evoked calcium influx [81] and a reduction
in the expression of calcium-buffering proteins. In AD
mouse models, increased levels of intracellular Ca2+ [82]
distorts the normal Ca2+ signaling and Ca2+-dependent
mechanisms and can indeed trigger the amyloidogenic
pathway [83–85]. Concretely, the AD brain is characterized
by a clear loss of synaptic processes and neuronal cell
bodies in the limbic and association cortices (reviewed in
ref. [1]). In normal aging, there is still a considerable
structural preservation in several brain areas including the
hippocampus [78, 86–88]. Therefore it is conceivable to
hypothesize that the shift from normal aging to AD could be
related to dysregulation of the integrated homeostatic net-
work caused by differences either in the levels of the endo-
genous ligand—adenosine [89], or in the expression of A2AR
that are increased upon aging and are further exacerbated in
AD (Fig. 1). To specifically check the endogenous activation
of A2AR, we have quantified the effect of blocking A2AR in
CA1 basal transmission, in age-impaired and age-unimpaired
animals. The fact that we observe a tendency towards an
increased effect of SCH 58261 in age-impaired subset,
without significant differences in the bulk mRNA A2AR levels
within the aged group, supports the first hypothesis.
A2AR and A1R form heteromers and, under physiological
conditions, adenosine preferentially activate A1R [90, 91] in
the hippocampus, which control glutamatergic neuro-
transmission, namely by a decrease in NMDAR-mediated
responses [92, 93]. In conditions where hippocampal
transmission is dysfunctional, there is an upregulation of
A2AR (reviewed in ref. [44]) together with an increased
release of ATP as a danger signal [94], which is the main
source of the extracellular adenosine activating A2AR [95].
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The signaling of these upregulated A2AR is shifted from a
PKC-dependent, controlled by inhibitory adenosine A1
receptors, towards a more disinhibited PKA-dependent
mechanism in aging and pathology [25, 30, 96], leading to
impaired synaptic plasticity and compromised memory
performance [26, 38, 39, 45]
This dysfunction is associated to an excitatory effect on
glutamatergic transmission, which we can postulate that it
may be mediated by non-heteromerized A2AR. Our results
in Tg(CaMKII-hA2AR) are in line with this hypothesis,
since we observe an aberrant constitutive activation of
A2AR, dependent on PKA [30], and consequent NMDAR,
both contributing to basal synaptic transmission, that could
not be observed in WT animals.
Long-term synaptic plasticity processes (LTP and LTD)
are the main neurophysiological correlate of memory
[7, 97]. Although the relation between hippocampal LTP
and memory is the most explored [98], there is also robust
evidence that altered hippocampal LTD affects memory
performance [12, 99], as shown in animal models of stress
[58] or of AD [59, 61]. We now report that Tg(CaMKII-
hA2AR) animals display memory impairments together with
a newly described LTD-to-LTP shift as a result of an
increase in Ca2+ influx dependent on NMDAR activation.
In fact, we observed a dose-dependent rescue of LTD in
slices from Tg(CaMKII-hA2AR) rats with the NMDAR
antagonist AP5. The concentration that fully restored LTD
in Tg(CaMKII-hA2AR) prevented it in WT animals. This
LTD in Tg(CaMKII-hA2AR) is NMDAR-dependent, since a
higher concentration of AP5, 100 µM, was able to com-
pletely abolish LTD. Accordingly, in primary cultures of
hippocampal neurons, A2AR activation directly increased
Ca2+ intracellular levels through NMDAR activation,
blocked by its selective antagonist AP5. These data strongly
indicate an A2AR–NMDAR interaction, consistent with our
synaptic plasticity results. Although in our paper we
observe a Ca2+ influx-dependent LTD-to-LTP shift, there
are reports that metabotropic NMDAR activity, independent
of calcium influx, can also induce LTD [100]. More rele-
vant, we have shown that the blockade of A2AR can restore
a similar LTD-to-LTP shift in aged and AD mice models,
strongly emphasizing A2AR as the pathophysiological
mediator involved in this synaptic shift.
We can postulate that NMDA receptor gating properties
are directly modulated by such an increase in glutamate
available to activate the ionotropic receptor. In such a case,
however, AMPA-mediated currents in Tg(CaMKII-hA2AR)
would be similarly increased, which we do not find. More-
over, when we transfected neurons with A2AR we could only
observe an increase in Ca2+ transients in transfected cells, but
not in the adjacent non-transfected neurons. If an overall
increase in glutamate were the only mechanism, then we
might expect some non-transfected neurons to be affected.
Therefore, other postsynaptic modifications due to an A2AR-
related increase in glutamate release and/or postsynaptic
A2AR contribution must be considered. Indeed, a postsynaptic
activation of A2AR can lead to downstream activation of
CREB in the hippocampus [27], and A2AR and mGluR5 can
directly interact and regulate NMDAR activity [53, 101].
Group I metabotropic glutamate receptors, namely
mGluR5, are postsynaptic and tightly coupled to NMDA
receptors [63, 64, 102], conferring them the ability to either
protect or exacerbate NMDAR-mediated toxicity depending
upon the model or cell type [103]. Upon activation by
glutamate release, preferentially upon strong synaptic acti-
vation, mGluR5 increase NMDAR-mediated Ca2+ currents
[65], by reducing the Mg2+ block [103] and triggering the
phosphorylation of NMDAR [64]. Previous studies hinted
at a possible A2AR-NMDAR crosstalk, since A2AR can
control expression [51, 102], recruitment [52] and the rate
of desensitization [53] of NMDAR. We and others have
provided compelling evidence of an A2AR-mGluR5 syner-
gistic interaction in the modulation of NMDAR-mediated
effects [53, 101, 102, 104]. Thus, mGluR5 is a likely can-
didate to act as a switch between A2AR and NMDAR, by
sensing glutamate and translating it into NMDAR over-
activation. Consistent with this hypothesis, we observe that
mGluR5 blockade prevents the downstream NMDAR
aberrant contribution in basal transmission and the LTD-to-
LTP shift, supporting the mGluR5-NMDAR interplay as
key player in the observed A2AR-induced physiopathology.
Aging is associated with a decline in cognitive function
that can, in part, be explained by changes in the mechanisms
of plasticity [78]. While some studies report increased
susceptibility to LTD during aging [15], others do not
observe alterations in LTD magnitude between young and
aged animals [16]. These discrepancies can be easily
explained by differences in rat strain, stimulation pattern
and Ca2+/Mg2+ ratio. In fact, the stimulation pattern used in
those studies (900 pulses, 1 Hz) does not elicit LTD in
young animals [15, 105], while we and others observe a
robust LTD with our LFS protocol [39, 61]. Moreover,
those age differences were reverted under elevated
Ca2+/Mg2+ ratio suggesting that aging is associated with a
shift in the threshold for LTD-induction rather than in the
LTD intrinsic capacity [16, 57]. Notably, the significant
correlation between LTD magnitude and the frequency of
LFS in Tg(CaMKII-hA2AR) animals confirms an age-
associated decrease in the threshold for LTD induction.
The fact that in aged CA1 pyramidal neurons there is an
increased duration of NMDAR-mediated responses [106]
which display an altered Ca2+ metabolism typified by larger
increases upon repeated stimulation [81, 107] further
strengthens our hypothesis. This increase in Ca2+ observed
in aging can lead to CREB dephosphorylation due to an
increase in calcineurin (PP2B) activity, strongly suggesting
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differential phosphatases and kinases activation as a key
mediator in these impairments [108, 109]. Alterations in
phosphatases and kinases could directly account for the
observed LTD-to-LTP shift. Importantly, we not only
showed that susceptibility to induction of LTD is associated
with memory impairments in aging, but also that the LTD
magnitude could be positively correlated with behavior
performance, consistent with previous data [57, 110].
The fact that an acute A2AR blockade is sufficient to
rescue the LTD-to-LTP shift favors the hypothesis that
A2AR blockade reestablishes the physiological signaling of
adenosine, rather than the receptor expression, which is
unlikely to occur at such a short time frame. Accordingly,
we have prior data showing that chronic KW6002 treatment
rescues cognitive and synaptic impairments induced by
stress, without altering A2AR levels [45].
There is a growing awareness of AD beginning as a
synaptic pathology [111], but very little is known con-
cerning LTD in these animals [112–114]. We now
demonstrate that, as our Tg(CaMKII-hA2AR) model, APP/
PS1 animals exhibit this LTD-to-LTP shift. Alterations in
NMDAR have been consistently linked to AD pathology
[59, 115–119] that we now report to be dependent on A2AR
activation. This abnormal A2AR/NMDAR crosstalk may
underlie the efficiency of A2AR blockade in reverting
memory deficits in animal models of AD [26, 35, 39].
The combined evidence of an increased A2AR expression
in hippocampal neurons from humans (aged individuals and
AD patients) and from animal models of these physiopatho-
logical conditions (Fig. 1; [26, 46, 68]) and the complete
rescue of the LTD-to-LTP shift upon A2AR acute blockade
stresses out A2AR as a putative pathological mediator
involved in calcium dysfunction underlying age- and AD-
related cognitive deficits, involving an aberrant recruitment of
mGluR5/NMDAR coupled to an altered Ca2+ influx (see
Supplementary Fig. 5 for a summary).
Methods
Human samples
The use of human samples was conducted in accordance
with the Helsinki Declaration as well as national ethical
guidelines. Protocols were approved by the Local Ethics
Committee and the National Data Protection Committee.
Human AD samples were provided by Valerie Buée-
Scherrer (INSERM UMR-S1172 “Alzheimer & Tauo-
pathies”, Lille Neurobank, Jean-Pierre Aubert Research
Center Univ. Lille-Nord de France, France) or by Pedro
Pereira and José Pimentel (Laboratório de Neuropatologia,
Hospital de Santa Maria, CHLN, EPE, Lisboa, Portugal).
Samples were collected from brains at 36 h post mortem.
Aged and young human samples were collected by Beatriz
S. da Silva (National Institute of Legal Medicine and For-
ensic Sciences, Coimbra, Portugal) and prepared by Paula
M. Canas (CNC-Center for Neurosciences and Cell Biology,
Univ. Coimbra, Coimbra, Portugal). After validation of their
quality (Pliássova et al. 2016 [141]) young (20–40 years
old), aged (60–75 years old) and AD (60–75 years old,
Braak stages 5–6) human forebrain and hippocampus were
used for histological analysis, Western blotting and qPCR as
indicated.
Animals
Animal procedures were performed in accordance with the
European Community guidelines (Directive 2010/63/EU),
Portuguese law on animal care (DL 113/2013), and
approved by the Instituto de Medicina Molecular Internal
Committee and the Portuguese Animal Ethics Committee
(Direcção Geral de Veterinária). Environmental conditions
were kept constant: food and water ad libitum, 21 ± 0.5 °C,
60 ± 10% relative humidity, 12 h light/dark cycles, 2 to 3
rats per cage or 3 to 4 mice per cage. Only male animals
were used in all experiments. Mice were sacrificed by cer-
vical dislocation and rats were sacrificed by decapitation
after anesthesia under halothane atmosphere. Male Tg
(CaMKII-hA2AR) Sprague-Dawley rats and their WT lit-
termates with matched age (8–14 weeks old) or aged WT
males (18–20 months old) were used for behavior and
electrophysiology experiments. Male WT and APP/PS1
mice (11–12 months old) were used for electrophysiology
experiments.
Generation and maintenance of transgenic animals
Transgenic rats with an overexpression of human A2AR cDNA
under the control of the Ca2+/calmodulin-dependent protein
kinase II (CaMKII) promoter, Tg(CaMKII-hA2AR), were
generated as previously described [30]. Expression of A2AR
was achieved in forebrain areas, mainly in the hippocampus
and cortex. Relevantly, the endogenous rA2AR mRNA levels
were not modified in the hippocampus [30]. Furthermore,
there was no changes in adenosine A1 receptor levels in the
hippocampus of Tg(CaMKII-hA2AR) animals [30].
Genotyping
Transgenic rats were identified by PCR (30 cycles, 58 °C
annealing temperature) of their genomic DNA isolated
from ear biopsies by the use of the CaMKII-hA2AR
transgene-specific primers and rat β-actin primers as an
internal control (Invitrogen, USA; see Supplementary
Table 1). APP/PS1dE9 transgenic mice on C57Bl6/J
background have been described elsewhere [120].
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Genotyping was done by PCR analysis of tail DNA (30
cycles, 60 °C annealing temperature) using transgene-
specific primers (APP and PrP) and tau as an internal
control (Supplementary Table 1).
Oral administration of the drug
KW6002 (istradefylline), a selective A2AR antagonist [121,
122], was diluted in the drinking water (0.025% methyl-
cellulose) and was orally administered to WT, Tg(CaMKII-
hA2AR) and aged animals, being continuously available.
The experimenter was blinded to genotype for the duration
of KW6002 administration. The weight of the animals and
the volume intake were assessed twice a week and the
concentration of the solution was adjusted so that the drug
intake was maintained at 5 mg kg–1 per day. The treatment
started at 5–7 weeks of age in WT and Tg(CaMKII-hA2AR)
and at 16 months of age in aged animals, and lasted for
1 month or 3 weeks, respectively, until sacrifice.
RNA extraction and quantitative real-time PCR
analysis (RT-qPCR)
Total RNA was extracted and purified using the RNeasy
Lipid Tissue Mini Kit (Qiagen, Germany). RNA quality
was assessed by NanoDrop 2000 (Thermo Scientific, USA)
analysis (A260/A280 ≈ 2; A260/A235 > 1.8). Total RNA (2 μg)
was reverse-transcribed using random primers and Super-
Script™ First-Strand Synthesis System for RT-PCR (Invi-
trogen). RT-qPCR analysis was performed on a Corbett
Rotor-gene 6000 apparatus (Qiagen, Germany) using Power
SYBR Green PCR Master Mix (Applied Biosystems, UK),
0.2 µM of each primer and 1/20 dilutions of total cDNA
(final concentration 0.4 ng/µl). The thermal cycler condi-
tions were 10 min at 95 °C, 40 cycles of a two-step PCR, 95
°C for 15 s followed by 60 °C for 25 s with a final thermal
ramp from 72 to 95 °C. Primer efficiencies
(E= 1 ± 0.02) were obtained from standard curves of serial
dilutions (slope and R2 around −3.3 and 0.99, respectively).
The sequences of the primers used (all from Invitrogen,
HPLC purified) are listed in Supplementary Table 1.
Reference genes were PPIA (cyclophilin A) and β-actin for
human tissues and PPIA, β-actin, Rpl13A and Pgk1 for rat
tissue. Amplifications were carried out in triplicate in two
independent runs, and according to the MIQE guidelines
[123]. The relative expression of target genes was deter-
mined by the comparative CT method [124].
In situ hybridization
The in situ hybridization technique was adapted from pre-
viously described methods [125]. The sections mounted on
RNAse free poly-L-lysine-coated slides were fixed in
freshly prepared 4% paraformaldehyde solution for 30 min
and rinsed in phosphate-buffered saline (PBS: 130 mM
NaCl, 7 mM Na2HPO4, 3 mM NaH2PO4). All sections were
dehydrated and dipped for 3 min in chloroform. After air
drying, the sections were incubated overnight at 42 °C with
0.35 × 106 cpm per section of 35S-labeled probes diluted in
hybridization buffer, which consisted of 50% formamide,
4xSSC (1xSSC: 0.15M NaCl, 0.015M sodium citrate, pH
7.4), 1 × Denhardt’s solution (0.02% polyvinylpyrrolidone,
0.02% bovine serum albumin (BSA), 0.02% Ficoll, 1%
sarcosyl, 0.02 M sodium phosphate at pH 7.4, 10% dextran
sulfate, 500 μg/ml yeast tRNA, 100 μg/ml salmon sperm
DNA, and 60 mM dithiothreitol). After hybridization, the
sections were rinsed for 4 × 15 min in 1xSSC at 55 °C,
dehydrated and covered with Hyperfilm-βmax film (Amer-
sham, Belgium) for 2 or 3 weeks. The oligonucleotide
probes were synthesized using an Applied Biosystems
381A DNA synthesizer or Eurogentec (Belgium) with a GC
to AT ratio between 45 and 65%. The human A2AR oli-
gonucleotide probe (CAGCCCTGGGAGTGGTTCTTGC
CCTCCTTTGGCTGACC-GCA) is complementary to
nucleotides 123–166 in a partial human cDNA sequence
[126] and has been previously used on human brain sections
[127]. The rat A2AR probe (CCGCTCCCCTGGCA
GGGGCTGGCTCTCCATC-TGCTTCAGCTG) is com-
plementary to nucleotides 604–645 of the rat cDNA
sequence [128]. Oligonucleotides were labeled with α-35S
dATP (DuPont-NEN, Belgium) at their 3' end by terminal
DNA deoxynucleotidylexotransferase (Gibco, Belgium)
and purified with a G50 column (Pharmacia, Belgium)
according to the manufacturer’s instructions.
Behavioral assessments
Rats were first handled for 5 days prior to behavioral tests.
Mazes were cleaned with a 30% ethanol solution between
each animal. Animals were randomized prior to behavioral
assessment and the experimenter blinded to genotype for
the duration of behavioral testing. All behavioral tests were
performed during the light phase between 8:00 a.m. and
6:00 p.m. in a sound attenuated room.
Morris water maze (MWM)
Spatial memory ability was evaluated in the MWM test, as
previously described [45]. WT and Tg(CaMKII-hA2AR)
animals were randomized and the experimenter blinded to
genotype for the duration of behavioral testing. The test was
performed over the course of 5 consecutive days and con-
sisted of a 4-day acquisition phase and a 1 day probe test.
The test was performed in a circular pool (1.8 m diameter,
0.6 m height), filled with water opacified with non-toxic
black paint and kept at 25 ± 2 °C. A round 8-cm in diameter
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platform was hidden 1 cm beneath the surface of the water
at a fixed position. Four positions around the edge of the
tank were used, dividing the tank into four quadrants: target
quadrant (T, quadrant where the platform was hidden), left
quadrant (L, quadrant on the left of the target quadrant),
right quadrant (R, quadrant of the right of the target quad-
rant) and opposite quadrant (O, quadrant on the opposite
side of the target quadrant). During the acquisition phase,
each animal was given four swimming trials per day (30-
mins inter-trial interval). A trial consisted of placing the
animal into the water facing the outer edge of the pool and
allowing the animal to explore and reach for the hidden
platform. If the animal reached the platform before 60 s, it
was allowed to remain there for 10 s. If the animal failed to
find the target before 60 s, it was manually guided to the
platform, where it was allowed to remain for 20 s. After the
end of each trial, animals were removed from the pool and
placed back to their home cages beneath heat lamps in order
to prevent temperature loss. During the probe test, the
platform was removed and animals were allowed to swim
freely for 60 s while recording the percentage of time spent
on each quadrant. The latency to find the platform during
the acquisition phase and the percentage of time in the
platform quadrant during the probe test were recorded and
analyzed using the Smart 2.5 tracking system (PanLab,
Barcelona) to evaluate hippocampal-dependent memory.
Swimming speed was also registered, as a measure of
possible motor deficits that could interfere with the ability to
perform the task.
Y-maze behavior test
Short-term reference memory was assessed in a sponta-
neous novelty-based spatial preference Y-maze test. The Y-
maze was performed in a two-trial recognition test in a Y-
shaped maze with three arms (each with 35 cm length x 10
cm width x 20 cm height), angled at 120° and with opaque
walls. Different cues were placed on the surrounding walls.
Allocation of arms was counterbalanced within each group.
On the first trial (learning trial), the animal explored the
maze for 10 min with only two arms opened (“start” and
“other” arm). Access to the third arm of the maze (“novel”
arm) was blocked by an opaque door. The rat was then
removed from the maze and returned to its home cage.
After 1 h, the animal was placed again in the “start” arm of
the maze, the door of the “novel” arm was removed and the
rat was allowed to explore the maze for 5 min (test trial).
Rat tracings were continuously monitored by an automated
tracking system (Smart 2.5, PanLab, Barcelona). Pre-
ference for the novel arm is considered a measure of short-
term reference memory. To exclude the possible con-
founding effect of alterations of locomotor activity, we
used the frequency of entrance into the arms (number of
transitions) as an indirect indicator of the general loco-
motor activity.
Electrophysiology experiments
After decapitation, the brain was rapidly removed and the
hippocampi were dissected free in ice-cold Krebs solu-
tion, which is composed of (mM): NaCl 124; KCl 3;
NaH2PO4 1.25; NaHCO3 26; MgSO4 1; CaCl2 2 and D-
glucose 10, continuously gassed with 95% O2 and 5%
CO2, pH 7.4. Transverse hippocampal slices (400 µm
thick) were obtained with a McIlwain tissue chopper and
field excitatory postsynaptic potentials (fEPSPs) were
recorded in the stratum radiatum of the CA1 area at 32 °
C, as previously described [45]. Tested drugs, SCH 58261
(50 and 100 nM), caffeine (30 µM), MPEP (5 µM) or AP5
(15, 50 and 100 µM), were added to the Krebs superfusion
solution (3 ml/min) after obtaining a stable 10 min base-
line. LTD was induced as previously [39] with three trains
of 2 Hz during 10 min separated by a 10-min interval, or
1200 pulses at 0.5, 1, and 2 Hz, with baseline fEPSPs of
0.5 mV/ms. The magnitude of synaptic plasticity was
calculated as percentage of change of fEPSP slope 50–60
min after LTD induction compared to baseline fEPSP (10
min before LTD induction). Recordings were performed
at 32 °C, 3 ml/min.
For patch-clamp recordings, transverse hippocampal
slices (300 µm) were cut in an oxygenated ice-cold solu-
tion containing (mM): 234 sucrose, 2.5 KCl, 1.25
NaH2PO4, 0.5 CaCl2, 10 MgSO4, 11 glucose, 26
NaHCO3. They were incubated at 37 °C for 1 h and then
maintained at room temperature (RT) for 0.5–5 h in an
oxygenated physiological solution (ACSF) containing (in
mM): 119 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2.5 CaCl2, 1.3
MgSO4, 11 glucose, 26 NaHCO3, pH 7.4. For recording,
slices were transferred into a submerged recording
chamber perfused with oxygenated ACSF at 3 ml/min at
32 °C and visualized under IR-DIC on a slidescope at x60
magnification (Scientifica Ltd., UK). Recordings were
made using a patchstar micromanipulator (Scientifica
Ltd.) connected to a Multiclamp700B amplifier and
Digidata 1440 acquisition system controlled by the
pClamp 10 software (Axon instruments, Molecular
Devices Ltd., USA). Patch pipettes were made of bor-
osilicate glass and shaped to a final resistance of
approximately 5 MΩ.
Current clamp experiments
Whole-cell patch-clamp experiments were performed in the
current clamp configuration [129] using a pipette solution
containing (mM): 135 gluconic acid (potassium salt: K-
gluconate), 5 NaCl, 2 MgCl2, 10 HEPES, 0.5 EGTA, 2
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ATP-Tris, and 0.4 Tris-GTP. After a tight seal ( > 1 GΩ) on
the cell body of the selected neuron was obtained, whole-
cell patch-clamp configuration was established, and cells
were left to stabilize for approximately 2 min before
recordings began. The resting (Vm) membrane potential
was first measured in the absence of any spontaneous fir-
ing, and only cells with Vm −55 mV were considered. We
then injected a minimum amount of current (150 pA) to
stimulate a sustained firing that we recorded for a few
minutes. Using this tonic firing, we measured the fast and
medium afterhyperpolarization potentials (fAHP and
mAHP, respectively) (Supplementary Fig. 3a, b). The
maximum rising slope, the overshoot and the action
potential (AP) half-width were also considered (Supple-
mentary Fig. 3a, b). The half-width value was calculated
considering the AP width measured at 50% of the peak
amplitude. These AP parameters were estimated without
taking into account the voltage drop across the pipette
resistance. To study the relationship between firing fre-
quency and current input (Supplementary Fig. 3c, d), we
first adjusted the membrane potential to −60 mV and then
injected 16 pulses of increasing intensity (from 100 to 850
pA, 200 ms duration). We also used these recordings to
measure the instantaneous firing frequency at the beginning
(onset frequency, fo, corresponding to the firing frequency
measured between the first and second APs in the spike
train) and at the end of the spike train (steady-state fre-
quency, fss, corresponding to the firing frequency measured
between the last two APs in the spike train) (Supplemen-
tary Fig. 3c). By plotting fo and fss as a function of injected
current (Supplementary Fig. 3e, f), we obtained informa-
tion on the spike frequency adaptation of these neurons. To
quantify the inward rectification time-dependent potential,
we first adjusted the membrane potential (Vh) to −60 mV
and injected 20 pulses of increasing intensity (from −100
pA to −2 nA, 600 ms duration). During the pulse, we
observed that the hyperpolarization reached a maximum
value (peak) and then decreased to stabilize to a steady-
state value (Supplementary Fig. 3g). We plotted the dif-
ference between the peak and the steady-state values as a
function of injected current to obtain indirect information
on the hyperpolarization-activated inward current (Ih)
(Supplementary Fig. 3h).
Voltage-clamp experiments
Whole-cell patch-clamp experiments were performed in
the voltage-clamp configuration [117, 130] using a pipette
solution containing (in mM): 117.5 cesium methane-
sulfonate, 15 CsCl, 10 tetraethylammonium chloride
(TEACl), 8 NaCl, 10 HEPES, 0.25 EGTA, 4 MgATP, 0.3
NaGTP; the pH was adjusted to 7.3 with CsOH. For all
experiments, slices were superfused with the oxygenated
ACSF at 32 °C in the continuous presence of 50 µM
picrotoxin (dissolved in Dimethylsulfoxide (DMSO),
Sigma-Aldrich, France) to block GABAergic transmis-
sion. The Schaffer collateral pathway was stimulated at
0.10 Hz using electrodes (glass pipettes filled with ACSF)
placed in the stratum radiatum. After a tight seal ( > 1 GΩ)
on the cell body of the selected neuron was obtained,
whole-cell patch-clamp configuration was established, and
cells were left to stabilize for approximately 2 min before
recordings began. To measure the paired-pulse ratio
(PPR), two stimuli were delivered with inter-spike inter-
vals between 50 and 200 ms. PPRs were calculated as the
ratio between the peak amplitude of EPSC2 and of EPSC1
(20 sweeps average per inter-spike interval) (Supple-
mentary Fig. 3i). To calculate the AMPAR/NMDAR ratio
(Fig. 2f), cells were held at −65 mV to record AMPAR
EPSCs and at + 40 mV to record NMDAR EPSCs.
AMPAR EPSCs amplitudes were calculated by averaging
30 consecutive EPSCs recorded at −65 mV and measur-
ing the peak compared to the baseline. NMDAR EPSCs
amplitudes were calculated by averaging 30 consecutive
EPSCs recorded at + 40 mV and measuring the ampli-
tude 60 ms after EPSC onset compared to the baseline.
Before starting I-V relationship measurements, stimulus
intensity was set to evoke an EPSC of approximately 100
pA at −60 mV, normalizing the response and thus the
number of recruited fibers. Liquid junction potential
was not corrected for whole-cell voltage-clamp
recordings. For EPSCNMDAR I-V relationship measure-
ments (Fig. 2g), pharmacologically isolated NMDAR
EPSCs were obtained in the presence of 6,7-dini-
troquinoxaline-2,3-dione (DNQX, 100 µM dissolved in
1% DMSO, Sigma-Aldrich). NMDAR EPSCs amplitudes
were calculated by averaging 15 consecutive EPSCs
recorded at voltages ranging from −70 mV to + 40 mV
in 10 mV steps. I–V relationships were normalized to the
NMDAR EPSC amplitude at + 40 mV (as+ 1). AMPAR
I–V relationships were recorded using an identical pro-
cedure, but in presence of R-2-amino-5-phosphono-
pentanoate (AP5, 50 µM dissolved in DMSO, Sigma-
Aldrich) and were normalized to the AMPAR
EPSC amplitude at −70 mV (as -1). The decay time of
pharmacologically isolated NMDAR EPSC, recorded
from cells voltage clamped at + 40 mV, was fit with a
double exponential function, using Clampfit software, to
calculate both slow and fast decay time constants, τslow
and τfast, respectively (Fig. 2i). The weighted time con-
stant (τweighted) was calculated using the relative con-
tribution from each of these components, applying the
formula: τw = [(af. τf) + (as. τs)]/(af + as), where af and
as are the relative amplitudes of the two exponential
components, and τf and τs are the corresponding time
constants (Fig. 2i).
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Primary neuronal cultures
Hippocampal neurons were cultured from 18 day Sprague-
Dawley rat embryos (Harlan, Barcelona, Spain) as pre-
viously described [131]. Briefly, embryos were collected in
Hank’s Balanced Salt Solution (HBSS, Corning, USA) and
rapidly decapitated. Meninges were removed, and whole
cortices (hippocampi and attached cortex) were dissociated
and incubated for 15 min in HBSS with 0.025% trypsin.
Cells were washed once with HBSS with 30% fetal bovine
serum (FBS), centrifuged three times, re-suspended in
Neurobasal Medium (Gibco–Life Technologies, USA)
supplemented with 2% B-27 supplement, 25 μM Glutamate,
0.5 mM glutamine, and 2 U/ml penicillin/streptomycin,
gently dissociated and filtered through a 70 μm strainer
(VWR, USA). Cells were plated on poly-D-lysine-coated
plates and grown for 14 days at 37 °C in a 5% CO2-humi-
dified atmosphere in the previously described supplemented
Neurobasal medium, in the absence of any positive selec-
tion for neurons.
Transfection of primary neuronal cultures
At DIV (day in vitro) 13, neurons were transfected as pre-
viously described [132]. A 33 ± 4% efficiency of transfec-
tion was obtained. At DIV 14, Ca2+ imaging experiments
and immunocytochemistry to confirm transfection were
performed.
Construct generation
Venus-A2AR construct was generated with the In-fusion HD
Cloning Kit (Clontech Takara, USA). Venus and A2AR
fragments were produced by using, respectively, the pair of
primers 5'-GTTTAAACTTAAGCTTATGGTGAGCAAGG
GCGAG-3' and 5'-GCTGCCCATGGTGGCCTTGTAC
AGCTCGTCCATG-3', and the pair of primers 5'-GCCAC-
CATGGGCAGCAGC-3' and 5'-AAACGGGCCCTCTAG
ATCAGCTGGGGGCGAACTC-3'. PCR fragments were
cloned into the vector pcDNA3.1(+ ) linearized with HindIII
and XbaI, and the resulting construct was verified by DNA
sequencing (GATC Biotech, Germany).
Ca2+ imaging
Primary neuronal cultures were plated at a density of 50 × 103
cells per well in 35mm glass bottom culture dishes (MatTek
Corporation, USA) previously coated with poly-D-lysine. At
DIV 14, neurons were loaded with Fura-2 AM
(5 µM, in external physiological solution with the following
composition in mM: NaCl 125, KCl 3, NaH2PO4 1.25, CaCl2
2, MgSO4 1, D-(+ )-glucose 10 and HEPES 10; pH 7.4
adjusted with NaOH) and incubated at 37 °C for 1 h. Cells
were then placed on a heated chamber installed in an inverted
microscope with epifluorescent optics and equipped with a
high speed multiple excitation fluorimetric system (Lambda
DG4, with a 175W Xenon arc lamp). Fura-2 AM loaded
neurons were sequentially excited both at 340 and 380 nm, for
250ms at each wavelength, and the emission fluorescence was
recorded at 510 nm with a charge-coupled device (CDD)
camera. Experiments were performed on cells with a baseline
fluorescence ratio around 0.5, which corresponds approxi-
mately to a [Ca2+]i of about 100 nM, considered the normal
[Ca2+]I [133, 134]. Cells with a baseline fluorescence ratio
above 1 were discarded. Experiments were performed at 37 °C
in a 5% CO2-humidified atmosphere. Drugs were applied
directly to the cells medium. All cells were challenged with
ionomycin (a Ca2+ ionophore; 2 µM) at the end of the
experiment and only those that responded were included,
confirming neuronal viability. Image data were recorded and
analyzed using the MetaFluor software (Universal Imaging,
West Chester, PA, USA).
Immunocytochemistry
Twenty-four hours after transfection, primary neurons
were washed with PBS and fixed with 4% paraformalde-
hyde for 10 min at RT, followed by a permeabilization
step with 0.5% Triton X-100 (Sigma–Aldrich) for 20 min
at RT. After blocking in 10% FBS for 30 min, the cells
were incubated with mouse anti-A2AR primary antibody
(1:100, mouse monoclonal, mab70192, Covalab, France)
overnight at 4 °C. After a 30-min washing with PBS, cells
were incubated with the secondary antibody Alexa Fluor
568 goat anti-mouse IgG (Life Technologies-Invitrogen)
for 1 h at RT. Finally, the cells were stained with Hoechst
33258 (1 mg/mL, Life Technologies;1:5000 in PBS) for 5
min and mounted in Dako mounting medium. Z-stack
images at 63 × magnification were acquired with a Zeiss
LSM 880 confocal microscope.
Immunohistochemistry
Brains were removed, stored in formaldehyde 4% aqueous
solution (VWR, USA) for 3 days, embedded in paraffin, and
cut into coronal sections of 2 μm. Slides were deparaffinized,
rehydrated and antigen retrieval was performed by microwave
heating in 0.01M citrate buffer pH= 6.0. For fluorescence
analysis, slices were then incubated with primary antibodies
selective for A2AR (1:100, mouse monoclonal, mab70192,
Covalab) and GFAP (1:250, rabbit polyclonal, G9269, Sigma-
Aldrich), MAP2 (1:500, rabbit polyclonal, ab32454, Abcam,
UK), SNAP25 (1:5000, rabbit polyclonal, S9684, Sigma-
Aldrich), synaptophysin (1:200, mouse monoclonal, S7568,
Sigma-Aldrich) or PSD95 (1:100, rabbit polyclonal, D27E11,
Cell Signaling Technology, UK) overnight at RT and washed
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for 20min with PBS before being incubated overnight at RT
with secondary antibodies (Alexa Fluor 488 donkey anti-rabbit
and Alexa Fluor 568 donkey anti-mouse 1:400, Life Tech-
nologies, USA). After washing for 20min, the sections were
incubated with Hoechst 33342 (12 μg/ml final concentration;
Thermo Scientific, USA), washed once and mounted in Dako
Mounting Medium (Agilent, USA). Z-stack images at 63 ×
magnification were acquired with a Zeiss LSM 880 Confocal
Microscope with Airyscan. The images were acquired with a
63 × objective, model Plan-Apochromat, a numerical aperture
of 1.40 and a working distance of 0.19mm. The images were
acquired with a voxel size of x:132 nm, y:132 nm, z:316 nm,
and the point spread function (PSF) monitored with beads of
175 nm was XY=min 205 ± 4 nm, max 234 ± 3 nm, and Z
478 ± 30 nm (emission wavelength 525 nm). Co-localization
analysis between A2AR and SNAP25/PSD95 was performed in
single plans with co-localization threshold tool in Fiji software
[135], which calculates several co-localization parameters and
generates an image with co-localized pixels stained in white
(Supplementary Fig. 2a, b). Compositional images of hippo-
campal formation were produced by tile stitching of images at
10 ×magnification acquired using Zeiss Axio Observer
Widefield microscope. For human samples, coronal sections
were stained with an anti-A2AR (1:100, mab70192, Covalab)
and developed using amplification (NovoLink™ Polymer
Detection System, Leica Biosystems, Germany) and horse-
radish peroxidase–diaminobenzidine (HRP-DAB) detection
systems. In parallel, an age-matched control section was used
as a negative control, where no primary antibody was used.
Samples were then mounted in Entellan® mounting medium
(Sigma-Aldrich). Optical density was measured using ImageJ
software in one field of 20 ×magnification and three fields of
40 ×magnification.
Electron microscopy
Tg(CaMKII-hA2AR) animals were anesthetized using iso-
flurane and fixed using perfusion pump with 0.1M phosphate
buffer containing 2% paraformaldehyde and 0.2% glutar-
aldehyde. After removal of the brain, 500 µm slices of hippo-
campus were collected using a Vibratome (Leica, Germany).
Immunoelectron microscopy of hippocampal slices was per-
formed according to Tokuyasu [136]. Slides were chemically
fixed in 0.1M phosphate buffer containing 2% paraformalde-
hyde and 0.2% glutaraldehyde, embedded in gelatine (Royal®
food grade gelatine) and cryo-preserved in 2.3M sucrose.
Gelatine blocks were frozen in liquid nitrogen and sectioned at
−120 °C using an cryo-ultramicrotome (UC7 and FC7, Leica)
to generate 70 nm sections, sections were collected and thaw in
a mixture of 2.3M sucrose and 2% methylcellulose. Immuno-
labeling was done in 1% bovine serum albumin and 0.8%
gelatine from cold water fish skin in PBS with polyclonal
rabbit anti-A2AR primary antibody (pab70273, 1:50, Covalab)
and 15 nm gold coupled Protein A (CMC Utrecht, 1:50). After
immuno-labeling, the sections were stained and mounted in a
mixture of 3% (aq.) uranyl acetate and 2% methylcellulose.
Images were taken using a Hitachi H-7650 electron microscope
at 100 kV acceleration. We counted the immunogold particles
in 40 micrographs (total of 72 synapses) of the CA1 area of Tg
(CaMKII-hA2AR) animals (according to ref. [137]) and eval-
uated blindly by two pathologists. We found an average of 2.4
particles/synapse. The gold labeling in synapses elements was
categorized into pre or post ( < 30 nm within the active zone)
and perisynaptic ( < 30 nm outside the active zone). No parti-
cles were found in the nucleus.
Fractionation
Subcellular fractionation was performed as described pre-
viously [138]. Briefly, WT and Tg(CaMKII-hA2AR) frozen
hippocampi were homogenized with Potter in a buffer con-
taining sucrose 0.32M and HEPES 10mM. After centrifuga-
tion (1000 g for 10min), the pellet was dissolved in a buffer
containing HEPES 4mM and EDTA 1mM. After cen-
trifugation (12,000 × g for 20min), the pellet was dissolved in a
buffer containing HEPES 20mM, NaCl 100mM, triton X-100
0.5%. After centrifugation (12,000 × g for 20min), the super-
natant is the non-postsynaptic density membrane fraction (non-
PSD95-enriched fraction), as confirmed by the detection of
enriched SNAP25 and the absence of PSD95 (Fig. 1h). The
pellet was dissolved in a buffer containing HEPES 20mM,
NaCl 0.15mM, triton X-100 1%, deoxycholic acid 1%, SDS
1% and centrifuged for 15min at 10,000 × g. The supernatant
is the postsynaptic density membrane fraction (PSD95-enriched
fractions), as demonstrated by the detection of enriched PSD95
and sparse SNAP25. Equal volumes of non-PSD95 and
PSD95-enriched fractions were diluted in sample buffer (see
western blotting section) and denatured by heating to 65 °C for
20min and used for western blot analysis.
Western blotting
Tissue was homogenized by sonication using RIPA buffer (50
mM Tris, 1mM EDTA, 150mM NaCl, 0.1% SDS, 1%
Tergitol-type NP-40, pH 8.0). The protein concentration was
determined using a BioRad DC Protein assay kit [based on ref.
[139])]. The appropriate volume of each sample was diluted in
water and sample buffer (70mM Tris pH 6.8, 6% glycerol, 2%
SDS, 120mM dithiothreitol and 0.0024% Bromophenol blue).
The samples were denatured at 65 °C for 20min. Based on the
protocol of Towbin et al. [140], samples and molecular weight
markers were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (10% for resolving and a 5% for
stacking gels) in denaturing conditions and electro-transferred
to Polyvinylidene fluoride (PVDF) membranes (GE Health-
care, UK). Membranes were blocked with 3% BSA in TBS-T
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0.1% (Tris-buffered saline with 0.1% Tween-20 solution, 200
nM Tris, 1.5M NaCl) for 1 h and incubated with primary
antibody (diluted in TBS-T, 3% BSA and 0.1% NaN3) over-
night at 4 °C. Primary antibodies were mouse anti-A2AR
(1:2000, 05-717, Upstate/Millipore, Germany), rabbit anti-
SNAP25 (1:10,000, S9684, Sigma), rabbit anti-pan-cadherin
(1:20,000, ab6529, Abcam), rabbit anti-PSD95 (1:1000,
D27E11 Cell Signaling Technology) and mouse anti-α-tubulin
(1:1000, sc-8035, Santa Cruz Biotechnology, USA). After
three washing periods of 10min with TBS-T, membranes were
incubated with horseradish peroxidase (HRP)—conjugated
anti-mouse or anti-rabbit secondary antibodies (1:10 000; Santa
Cruz Biotechnology) (in 5% nonfat dry milk) for 1 h at RT.
After 30min of washing with TBS-T, chemiluminescent
detection was performed with Enhanced chemiluminescence
(ECL) western blotting detection reagent (GE Healthcare)
using X-Ray films (Fujifilm, Japan). Optical density was
determined with Image-J software and normalized to the
respective pan-cadherin or tubulin band density.
Drugs
The A2AR selective antagonist, 2-(2-furanyl)-7-(2-pheny-
lethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]¬pyrimi¬din-
5-amine (SCH 58261) and the A2AR selective agonist
2-[p-(2-Carboxyethyl)-phenylethylamino]-5’-N-ethylcarbox-
amidoadenosine (CGS 21680) were purchased from Tocris
(UK). GABA receptor antagonist picrotoxin, AMPA recep-
tor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) and
NMDA receptor antagonist (2 R)-amino-5-phosphonovaleric
acid (AP5) were purchased from Sigma-Aldrich. mGluR5
antagonist 6-Methyl-2-(phenylethynyl)-pyridine hydro-
chloride (MPEP) was purchased from Enzo Life Sciences
(USA). These drugs were diluted in the assay solution
from 5mM or 1 mM stock aliquots made in DMSO or
water stored at –20 °C. All other reagents used were of
the highest purity available either from Merck or
Sigma–Aldrich.
Statistical analysis
All statistical analyses were performed with GraphPad
Prism software. Values are presented as mean ± s.e.m. in
figure legends. Statistical analyses were designed using the
assumption of normal distribution and similar variance
among groups, as previously tested. Statistical comparisons
included two-sided unpaired t-test, one or two-way
ANOVA followed by a Bonferroni’s or Tukey’s multiple
comparison post hoc tests as specified in the figure legends.
P-values of < 0.05 were considered to be statistically sig-
nificant. The sample size was determined based on Power
Analysis or similar experiments carried out in the past.
Power Analysis was performed using G-power in order to
estimate the number of animals required, for a signal-to-
noise ratio of 1.4 and 80% to 90% power assuming a 5%
significance level.
Data availability
For detailed information on experimental design please see
the provided Reproducibility Checklist. Full-length gels and
blots with molecular weight standards are provided in
Supplementary Fig. 6. All the software used to data analysis
is commercially available and the respective information is
provided in each respective section. The data that support
the findings of this study are available from the corre-
sponding authors upon reasonable request.
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